PT4245298T - Nova formulação para administração oral, compreendendo 1- (5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina - Google Patents

Nova formulação para administração oral, compreendendo 1- (5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina

Info

Publication number
PT4245298T
PT4245298T PT219071487T PT21907148T PT4245298T PT 4245298 T PT4245298 T PT 4245298T PT 219071487 T PT219071487 T PT 219071487T PT 21907148 T PT21907148 T PT 21907148T PT 4245298 T PT4245298 T PT 4245298T
Authority
PT
Portugal
Prior art keywords
methylmethamine
pyrrol
difluorophenyl
fluorophenyl
sulfonyl
Prior art date
Application number
PT219071487T
Other languages
English (en)
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of PT4245298T publication Critical patent/PT4245298T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT219071487T 2020-12-18 2021-12-17 Nova formulação para administração oral, compreendendo 1- (5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina PT4245298T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200178281 2020-12-18

Publications (1)

Publication Number Publication Date
PT4245298T true PT4245298T (pt) 2026-03-24

Family

ID=82059437

Family Applications (1)

Application Number Title Priority Date Filing Date
PT219071487T PT4245298T (pt) 2020-12-18 2021-12-17 Nova formulação para administração oral, compreendendo 1- (5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina

Country Status (14)

Country Link
US (1) US20250073205A1 (pt)
EP (1) EP4245298B1 (pt)
JP (1) JP7777136B2 (pt)
KR (2) KR102852448B1 (pt)
CN (1) CN116761589A (pt)
CR (1) CR20230266A (pt)
DK (1) DK4245298T3 (pt)
FI (1) FI4245298T3 (pt)
GE (2) GEAP202316269A (pt)
PT (1) PT4245298T (pt)
TW (1) TW202241409A (pt)
UA (1) UA130030C2 (pt)
WO (1) WO2022131844A1 (pt)
ZA (1) ZA202306242B (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
BRPI0720472A2 (pt) 2006-12-22 2014-01-14 Yuhan Corp Dispersão sólida contendo revaprazan e processo para a preparação da mesma
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EA201171284A1 (ru) 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Новая технология изготовления напроксена
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
JP2015531365A (ja) 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR101910902B1 (ko) * 2016-11-03 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR102373089B1 (ko) * 2017-03-30 2022-03-11 한미약품 주식회사 이부프로펜 및 아세트아미노펜을 포함하는 약제학적 조성물 및 이의 제조방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
EP4245298A1 (en) 2023-09-20
UA130030C2 (uk) 2025-10-15
TW202241409A (zh) 2022-11-01
EP4245298A4 (en) 2024-10-30
CR20230266A (es) 2023-07-19
DK4245298T3 (en) 2026-03-30
JP7777136B2 (ja) 2025-11-27
KR20250133258A (ko) 2025-09-05
GEP20247647B (en) 2024-07-25
GEAP202316269A (en) 2023-10-10
EP4245298B1 (en) 2026-01-21
JP2024500406A (ja) 2024-01-09
WO2022131844A1 (ko) 2022-06-23
KR102852448B1 (ko) 2025-08-29
CN116761589A (zh) 2023-09-15
ZA202306242B (en) 2025-01-29
KR20220088362A (ko) 2022-06-27
US20250073205A1 (en) 2025-03-06
FI4245298T3 (fi) 2026-04-17

Similar Documents

Publication Publication Date Title
PE20120797A1 (es) Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
RU2007146113A (ru) Замещенные арилпиразолы в качестве агентов для уничтожения паразитов
HUE053741T2 (hu) Új sav hozzáadásával nyert 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)szulfonil)-4-metoxi-1H-pirrol-3-YL)-N-metilmetánamin só
CL2013000884A1 (es) El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer.
FI3848027T3 (fi) Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita
BR112017006242A2 (pt) derivados de naftiridina como antagonistas de integrina alfa v beta 6 para o tratamento de, por exemplo, doenças fibróticas
EA201790454A2 (ru) Новая кристаллическая форма соли 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n- метилметанамина
IL259609A (en) Method for producing 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(4,2,1-triazol-1-yl)propan-2-ol
PE20151555A1 (es) Agentes inductores de la apoptosis para tratar el cancer y enfermedades inmunes y autoinmunes
FI4079293T3 (fi) Nestemäinen farmaseuttinen 1-(5-(2,4-difluorifenyyli)-1-((3-fluorifenyyli)sulfonyyli)-4-metoksi-1h-pyrrol-3-yyli)-n-metyylimetaaniamiini-koostumus
DK3724191T3 (da) 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling
CL2012003162A1 (es) Formulacion farmaceutica de administracion oral que comprende un compuesto derivado de 1-(beta-d-glucopiranosil)-3-(2-tienilmetil)benceno sustituido, un diluyente , un desintegrante, un aglutinante y un lubricante; composición farmaceutica; y metodo para tratar un trastorno mediado por transportadores de glucosa dependientes de sodio.
BR112018008575A2 (pt) combinações de composto ativo que compreendem um derivado de (tio)carboxamida e um composto fungicida
PT4245298T (pt) Nova formulação para administração oral, compreendendo 1- (5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina
ECSP23089215A (es) Recipiente para medicamentos que comprende una composición farmacéutica líquida de 1-(5-(2,4-difluorofenil)-1-((3- fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
EP4356900A4 (en) NEW INJECTABLE FORMULATION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE
EP4349324A4 (en) DRUG CONTAINER CONTAINING A LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUOROPHENYL))-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE
EP4344701A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID
ECSP23089201A (es) Nueva formulación para inyección que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
MX2022005199A (es) Inhibidores de ssao y uso de los mismos.
NZ594157A (en) Sulfonamide compounds for the treatment of respiratory disorders
BR112023026510A2 (pt) Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina
DK2089030T3 (da) Middel til profylakse eller behandling af alkoholafhængighed eller lægemiddelafhængighed
EP3932908A4 (en) SUBSTITUTED PYRAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
AR132113A1 (es) Forma sólida de derivados de pirrolidona como activador de glucoquinasa